Elan Skelaxin FTC Inquiry Ongoing Despite Halt To Patent Listing Investigation
Executive Summary
The Federal Trade Commission is continuing its inquiry into Elan's competitive practices for Skelaxin despite halting an investigation of whether the firm wrongfully listed a patent for the muscle relaxant
You may also be interested in...
King/Elan Deal Proceeds; Skelaxin Royalties Will Offset Lower Purchase Price
King will pay Elan royalties on sales of the muscle relaxant Skelaxin under a restructured agreement for Elan's primary care business
King/Elan Deal Proceeds; Skelaxin Royalties Will Offset Lower Purchase Price
King will pay Elan royalties on sales of the muscle relaxant Skelaxin under a restructured agreement for Elan's primary care business
King Acknowledges Medicaid Accounting Errors; Wants Out Of Elan Deal
King has discovered errors in its Medicaid rebate accounting, the firm disclosed March 31